You are here

Home » Content

Erkeklerde Osteoporoza Birinci Basamak Bakış

MALE OSTEOPOROSIS IN PRIMARY CARE

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Osteoporosis is a disease of the musculoskeletal system which increases the risk of bone fractures. It is defined as low bone mineral density expected for age, gender and race. The prevalence of osteoporosis is 4-6% and the prevalence of osteopenia is 33-47% among men older than 50 years. Routine screening is not recommended for men unless there are risk factors. Recommended therapies for osteoporosis in men are testosterone replacement therapy for hypogonadal patients, biphosphonates and parathor-mone besides calcium, vitamin D and exercise.
Bookmark/Search this post with
Abstract (Original Language): 
Osteoporoz, kemiğin kırık riskini artıran bir iskelet sistemi hastalığıdır. Kişinin kemik kitlesinin yaş, cinsiyet ve ırkına göre beklenen değerlerin altında olması şeklinde tanımlanır. Elli yaş üzerindeki erkeklerin %4-6'sında osteoporoz, %33-47'sinde osteopeni vardır. Erkeklerde risk faktörleri yoksa rutin tarama önerilmemektedir. Erkeklerde osteoporoz tedavisinde kalsiyum, D vitamini ve egzersi¬zin yanı sıra kabul edilen tedaviler hipogonadal erkeklerde testos¬teron replasmanı, bifosfonatlar ve parathormondur
FULL TEXT (PDF): 
PDF icon arastrmx_116859_11_pp_87-91.pdf
  • 2
87-91
  • Turkish

REFERENCES

References: 

1.
Akgü
n K. İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri, Osteoporoz Sempozyumu, 26 Şubat 1999, İstanbul, 63-72.
2. Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician 2003; 67: 1521-6.
3.
Nationa
l Osteoporosis Foundation. Osteoporosis-men. http://www.nof. org/men adresinden 07/07/2006 tarihinde erişilmiştir.
4. Siminoski K, Leslie WD, Frame H ve ark. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J 2005; 56: 178-88.
5. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 1117-23.
6. Biberoğlu S. Osteoporoz tedavisinde yenilikler. Erkek osteoporozu. Turkish Journal of Endocrinology and Metabolism 2003; 7: 104-5.
7. National Institutes of Health. Osteoporosis and Related Bone Diseases-National Resource Center. Osteoporosis in Men 2005.
8.
Kocaoğl
u S, Ceceli E, Karaoğlan B, Yorgancıoğlu ZR. Toplumumuzdaki Erkeklerde Osteoporoz. Osteoporoz Dünyasından 2002; 8: 178-81. http://www.osteoporozdunyasindan.com/sayilar/14/178-181.pdf adresinden 09/07/2006 tarihinde erişilmiştir.
9. Melton LJ, Kan SH, Wahner HW, Riggs BL. Lifetime fracture risk: An approach to hip fracture risk assessment based on bone mineral density and age. J Clin Epidemiol 1988; 41: 985-94.
10. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA. Lifetime risk of hip fractures is underestimated. Osteoporos Int 1998; 8: 599-603.
11. Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA.
Symptomatic fracture incidence in elderly men and women: The Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 1994; 4: 277-82.
12. Kaufman JM, Johnell O, Abadie E ve ark. Background for studies on the treatment of male osteoporosis: State of the art. Ann Rheum Dis 2000; 59:
765-72.
13. Jacobsen SJ, Goldberg J, Miles TP, Brody JA, Stiers W, Rimm AA. Race and sex differences in mortality following fracture of the hip. Am J Public Health 1992; 82: 1147-50.
14. De Laet CE, van Hout BA, Burger H, Hofman A, Pols HA. Bone density and risk of hip fracture in men and women: Cross sectional analysis. BMJ
1997; 315: 221-5.
15. Erkeklerde osteoporoz. http://www.hacettepem.org.tr adresinden 09/07/2006 tarihinde erişilmiştir.
16. Akpınar E. Menopoz ve postmenopozal osteoporoza birinci basamak yaklaşım. Türkiye'de Aile Hekimliği Dergisi 2006; 1: 63-72.
17.
Finkelstei
n JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM.
The effects of parathryroid hormone, alendronate, or both in men with osteo¬porosis. N Engl J Med 2003; 349: 1216-26.
18. World Health Organisation. Guidelines for preclinical evaluations and clini¬cal trials in osteoporosis. 1998.
19. Eastell R, Boyle IT, Compston J, Cooper C, Fogelman I, Francis RM.
Management of male osteoporosis: Report of the UK Consensus Group. QJM
1998; 91: 71-92.
20. Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS. Declining bone mass in men with chronic pulmonary disease. Chest 1999; 116: 1616-24.
21. Adams JS, Soing CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann
Intern Med 1999; 130: 658-60.
22. Sepici V. Osteoporoz tanısında laboratuar testleri. http://www.osteoporoz. org/html/laboratuvar/html adresinden 07/07/2006 tarihinde erişilmiştir.
23. Finkelstein JS, Klibanski A, Neer RM ve ark. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J
Clin Endocrinol Metab 1989; 69: 776.
24. Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone
replacement in older hypogonadal men: A 12 month randomized controlled
trial. J Clin Endocrinol Metab 1997; 8: 1661-7.
25. Kamel HK. Male osteoporosis: new trends in diagnosis and therapy. Drugs
Aging 2005; 22: 741-8.
26. World Health Organisation and Agriculture Organisation of the United Nations Vitamin and mineral requirements in human nutrition, 2004.

Thank you for copying data from http://www.arastirmax.com